Latest News

Amryt Pharma new drug application for rare skin condition fast-tracked by the US Food & Drug Adminis


Amryt Pharma PLC (NASDAQ:AMYT; AIM:AMYT) has been granted a priority review of its new drug application for Oleogel-S10 by the US drugs watchdog with a decision expected on or before November 30.

The US Food & Drug Administration fast-track has shortened the regulatory timeline from 10 months to six.

Oleogel-S10 has been developed to treat junctional and dystrophic epidermolysis bullosa, where the skin is fragile to even the lightest touch.

It is a rare condition that affects young children and adults and there is currently no approved treatment.

Chief executive Joe Wiley said confirmation of the November 30 PDUFA date – the deadline for an FDA decision – kept Amryt on track for approval for the breakthrough new treatment by the year-end.

“If approved, Oleogel-S10 could potentially be an important treatment option for patients suffering from EB, a serious and debilitating disease for which there are currently no approved treatments and our launch plans for Oleogel-S10 are well advanced,” he added.

European Lithium “at forefront of Europe’s battle for white gold”, Spark Plus reports

Previous article

Pan African renews mining rights at Barberton for next 30 years

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News